Stockreport

Revolution Medicines: It's Full Steam Ahead, But I Wouldn't Buy At These Levels [Seeking Alpha]

Revolution Medicines, Inc.  (RVMD) 
PDF Summary Revolution Medicines' promising KRAS inhibitors show potential in treating difficult cancers, but the $7 billion valuation is high for a pre-commercial entity [Read more]